iCAD (NASDAQ:ICAD) Share Price Passes Above 200 Day Moving Average of $1.51

iCAD, Inc. (NASDAQ:ICAD)’s stock price passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.51 and traded as high as $1.54. iCAD shares last traded at $1.42, with a volume of 148,444 shares trading hands.

Analyst Ratings Changes

Separately, StockNews.com raised iCAD from a “sell” rating to a “hold” rating in a research note on Thursday, August 22nd.

iCAD Price Performance

The stock has a market capitalization of $37.69 million, a P/E ratio of -11.83 and a beta of 1.51. The firm has a 50-day simple moving average of $1.39 and a 200 day simple moving average of $1.51.

iCAD (NASDAQ:ICAD) last posted its earnings results on Tuesday, August 13th. The technology company reported ($0.07) EPS for the quarter. iCAD had a negative return on equity of 13.59% and a negative net margin of 15.67%. The business had revenue of $5.03 million for the quarter.

Institutional Investors Weigh In On iCAD

Hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC grew its position in shares of iCAD by 55.6% during the 1st quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock worth $34,000 after buying an additional 7,604 shares during the period. Salem Investment Counselors Inc. bought a new stake in iCAD in the first quarter valued at $119,000. AMH Equity Ltd acquired a new position in shares of iCAD during the first quarter valued at about $207,000. Perritt Capital Management Inc. boosted its position in shares of iCAD by 7.5% during the 1st quarter. Perritt Capital Management Inc. now owns 139,983 shares of the technology company’s stock worth $225,000 after purchasing an additional 9,717 shares in the last quarter. Finally, Perritt Capital Management Inc grew its stake in shares of iCAD by 14.2% in the 2nd quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company’s stock valued at $208,000 after buying an additional 19,917 shares during the period. 24.61% of the stock is currently owned by institutional investors.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.